BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34099270)

  • 1. Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics.
    Zuliani L; Marangoni S; De Gaspari P; Rosellini I; Nosadini M; Fleming JM; De Riva V; Galloni E; Perini F; Frigo AC; Sartori S; Zoccarato M; Giometto B
    J Neuroimmunol; 2021 Aug; 357():577598. PubMed ID: 34099270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes expressing neuronal autoantigens induced immune response in antibody-positive autoimmune encephalitis.
    Gu J; Jin T; Li Z; Chen H; Xia H; Xu X; Gui Y
    Mol Immunol; 2021 Mar; 131():164-170. PubMed ID: 33446390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three cases of antibody-LGI1 limbic encephalitis and review of literature.
    Bing-Lei W; Jia-Hua Z; Yan L; Zan Y; Xin B; Jian-Hua S; Hui-Juan W
    Int J Neurosci; 2019 Jul; 129(7):642-648. PubMed ID: 30112956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations.
    Zuliani L; Nosadini M; Gastaldi M; Spatola M; Iorio R; Zoccarato M; Mariotto S; De Gaspari P; Perini F; Ferrari S; Evoli A; Sartori S; Franciotta D; Giometto B
    Neurol Sci; 2019 Oct; 40(10):2017-2030. PubMed ID: 31161339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
    Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
    BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limbic encephalitis with LGI1 antibodies in a 14-year-old boy.
    Schimmel M; Frühwald MC; Bien CG
    Eur J Paediatr Neurol; 2018 Jan; 22(1):190-193. PubMed ID: 28919330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies.
    Ji T; Huang Z; Lian Y; Wang C; Zhang Q; Li J
    BMC Neurol; 2020 Sep; 20(1):336. PubMed ID: 32894089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over 10-year follow-up of limbic encephalitis associated with anti-LGI1 antibodies.
    Agazzi P; Bien CG; Staedler C; Biglio V; Gobbi C
    J Neurol; 2015 Feb; 262(2):469-70. PubMed ID: 25504306
    [No Abstract]   [Full Text] [Related]  

  • 9. Practical issues in measuring autoantibodies to neuronal cell-surface antigens in autoimmune neurological disorders: 190 cases.
    Kaneko J; Kanazawa N; Tominaga N; Kaneko A; Suga H; Usui R; Ishima D; Kitamura E; Akutsu T; Yoshida K; Nishiyama K; Iizuka T
    J Neurol Sci; 2018 Jul; 390():26-32. PubMed ID: 29801900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of Antibody-Positive Autoimmune Encephalitis in Southwest China: A Multicenter Study.
    Gu Y; Zhong M; He L; Li W; Huang Y; Liu J; Chen Y; Xiao Z
    Front Immunol; 2019; 10():2611. PubMed ID: 31781111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
    Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
    Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.
    van Sonderen A; Thijs RD; Coenders EC; Jiskoot LC; Sanchez E; de Bruijn MA; van Coevorden-Hameete MH; Wirtz PW; Schreurs MW; Sillevis Smitt PA; Titulaer MJ
    Neurology; 2016 Oct; 87(14):1449-1456. PubMed ID: 27590293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of moyamoya disease after non-herpetic acute limbic encephalitis: A case report.
    Takahashi Y; Mikami T; Suzuki H; Komatsu K; Yamamoto D; Shimohama S; Houkin K; Sugita S; Hasegawa T; Mikuni N
    J Clin Neurosci; 2018 Jul; 53():250-253. PubMed ID: 29731274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide-responsive Lgi1-related limbic encephalitis with basal ganglia hypermetabolism.
    Renard D; Collombier L; Lippi A; Honnorat J; Thouvenot E
    Acta Neurol Belg; 2016 Sep; 116(3):379-81. PubMed ID: 26590598
    [No Abstract]   [Full Text] [Related]  

  • 15. [Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications].
    Dalmau J; Bataller L
    Neurologia; 2007 Oct; 22(8):526-37. PubMed ID: 18000762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune-mediated encephalitis.
    Demaerel P; Van Dessel W; Van Paesschen W; Vandenberghe R; Van Laere K; Linn J
    Neuroradiology; 2011 Nov; 53(11):837-51. PubMed ID: 21271243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis.
    Wang Y; Yu Y; Hu Y; Li Y; Song F; Wang Y
    Front Neurol; 2020; 11():280. PubMed ID: 32431657
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody-LGI 1 autoimmune encephalitis manifesting as rapidly progressive dementia and hyponatremia: a case report and literature review.
    Li X; Yuan J; Liu L; Hu W
    BMC Neurol; 2019 Feb; 19(1):19. PubMed ID: 30732585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syndrome and outcome of antibody-negative limbic encephalitis.
    Graus F; Escudero D; Oleaga L; Bruna J; Villarejo-Galende A; Ballabriga J; Barceló MI; Gilo F; Popkirov S; Stourac P; Dalmau J
    Eur J Neurol; 2018 Aug; 25(8):1011-1016. PubMed ID: 29667271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LGI1 related limbic encephalitis and response to immunosuppressive therapy.
    Kaymakamzade B; Kansu T; Tan E; Dericioğlu N
    J Neurol; 2011 Nov; 258(11):2075-7. PubMed ID: 21556879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.